Literature DB >> 3170589

Modification of low density lipoprotein by lipoprotein lipase or hepatic lipase induces enhanced uptake and cholesterol accumulation in cells.

M Aviram1, E L Bierman, A Chait.   

Abstract

Incubation of low density lipoprotein(s) (LDL) with either lipoprotein lipase or hepatic lipase led to modification of the core lipid composition of LDL. Both lipases modified LDL by substantially reducing core triglyceride content without producing marked differences in size, charge, or lipid peroxide content in comparison to native LDL. The triglyceride-depleted forms of LDL that result from treatment with these two enzymes were degraded at approximately twice the rate of native LDL by human monocyte-derived macrophages (HMDM). Lipase-modified LDL degradation was inhibited by chloroquine, suggesting lysosomal involvement in LDL cellular processing. The increased degradation by macrophages of the LDL modified by these lipases was accompanied by enhanced cholesterol esterification rates, as well as by an increase in cellular free and esterified cholesterol content. In a patient with hepatic triglyceride lipase deficiency, degradation of the triglyceride-rich LDL by HMDM was approximately half that of normal LDL. Following in vitro incubation of LDL from this patient with either lipoprotein or hepatic lipase, lipoprotein degradation increased to normal. Several lines of evidence indicate that LDL modified by both lipases were taken up by the LDL receptor and not by the scavenger receptor. 1) The degradation of lipase-modified LDL in nonphagocytic cells (human skin fibroblast and arterial smooth muscle cells) as well as in phagocytic cells (HMDM, J-774, HL-60, and U-937 cell lines) could be dissociated from that of acetylated LDL and was always higher than that of native LDL. A similar pattern was found for cellular cholesterol esterification and cholesterol mass. 2) LDL receptor-negative fibroblasts did not degrade lipase-modified LDL. 3) A monoclonal antibody to the LDL receptor inhibited macrophage degradation of the lipase-modified LDL. 4) Excess amounts of unlabeled LDL competed substantially with 125I-labeled lipase-modified LDL for degradation by both macrophages and fibroblasts. Thus, lipase-modified LDL can cause significant cholesterol accumulation in macrophages even though it is taken up by LDL and not by the scavenger receptor. This effect could possibly be related to the reduced triglyceride content in the core of LDL, which may alter presentation of the LDL receptor-binding domain of apolipoprotein B on the particle surface, thereby leading to increased recognition and cellular uptake via the LDL receptor pathway.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3170589

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase.

Authors:  M Shimada; S Ishibashi; T Inaba; H Yagyu; K Harada; J I Osuga; K Ohashi; Y Yazaki; N Yamada
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  ApoB-100-containing lipoproteins are major carriers of 3-iodothyronamine in circulation.

Authors:  Gouriprassana Roy; Ekaterina Placzek; Thomas S Scanlan
Journal:  J Biol Chem       Date:  2011-11-28       Impact factor: 5.157

3.  Lipoprotein lipase is synthesized by macrophage-derived foam cells in human coronary atherosclerotic plaques.

Authors:  K D O'Brien; D Gordon; S Deeb; M Ferguson; A Chait
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

4.  Phospholipase D-modified low density lipoprotein is taken up by macrophages at increased rate. A possible role for phosphatidic acid.

Authors:  M Aviram; I Maor
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

5.  Model of human low-density lipoprotein and bound receptor based on cryoEM.

Authors:  Gang Ren; Gabby Rudenko; Steven J Ludtke; Johann Deisenhofer; Wah Chiu; Henry J Pownall
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

6.  Expression of lipoprotein lipase mRNA and secretion in macrophages isolated from human atherosclerotic aorta.

Authors:  L Mattsson; H Johansson; M Ottosson; G Bondjers; O Wiklund
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

7.  Lipoprotein lipase-mediated uptake and degradation of low density lipoproteins by fibroblasts and macrophages.

Authors:  S C Rumsey; J C Obunike; Y Arad; R J Deckelbaum; I J Goldberg
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

8.  Hepatic lipase expression in macrophages contributes to atherosclerosis in apoE-deficient and LCAT-transgenic mice.

Authors:  Zengxuan Nong; Herminia Gonzalez-Navarro; Marcelo Amar; Lita Freeman; Catherine Knapper; Edward B Neufeld; Beverly J Paigen; Robert F Hoyt; Jamila Fruchart-Najib; Silvia Santamarina-Fojo
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

9.  Apolipoprotein E localization in human coronary atherosclerotic plaques by in situ hybridization and immunohistochemistry and comparison with lipoprotein lipase.

Authors:  K D O'Brien; S S Deeb; M Ferguson; T O McDonald; M D Allen; C E Alpers; A Chait
Journal:  Am J Pathol       Date:  1994-03       Impact factor: 4.307

10.  Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix.

Authors:  S Eisenberg; E Sehayek; T Olivecrona; I Vlodavsky
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.